financetom
Business
financetom
/
Business
/
Update: Adobe Fiscal Q1 Non-GAAP Earnings, Revenue Increase; $25 Billion Stock Buyback Authorized -- Shares Fall Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Adobe Fiscal Q1 Non-GAAP Earnings, Revenue Increase; $25 Billion Stock Buyback Authorized -- Shares Fall Pre-Bell
Mar 15, 2024 6:03 AM

08:39 AM EDT, 03/15/2024 (MT Newswires) -- (Updates headline and last paragraph with latest share price movement.)

Adobe Systems (ADBE) late Thursday reported fiscal Q1 non-GAAP net income of $4.48 per diluted share, up from $3.80 a year earlier.

Analysts polled by Capital IQ expected $4.38.

Revenue for the quarter ended March 1 was $5.18 billion, up from $4.66 billion a year earlier.

Analysts expected $5.15 billion.

For Q2, the software company is projecting non-GAAP EPS of $4.35 to $4.40 on revenue of $5.25 billion to $5.30 billion.

Analysts polled by Capital IQ are looking for $4.37 and $5.31 billion, respectively.

Separately, Adobe said it has authorized the repurchase of up to $25 billion of its shares through mid-March 2028.

Adobe shares were down more than 11% in recent Friday premarket activity.

Price: 505.95, Change: -64.5, Percent Change: -11.31

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Adaptimmune Therapeutics Says Unit Gets Termination Notice for Strategic Collaboration With Genentech
Adaptimmune Therapeutics Says Unit Gets Termination Notice for Strategic Collaboration With Genentech
Apr 12, 2024
09:08 AM EDT, 04/12/2024 (MT Newswires) -- Adaptimmune Therapeutics plc ( ADAP ) said Friday that its Adaptimmune Ltd. unit has received a notice of termination of the strategic collaboration and license agreement with Genentech and F. Hoffman-La Roche. Under the agreement, which was signed in 2021, Genentech and Adaptimmune worked together to develop two types of allogeneic T-cell therapies,...
Nike bosses plan 'biggest' Olympics spend as marketing ramps up
Nike bosses plan 'biggest' Olympics spend as marketing ramps up
Apr 12, 2024
PARIS, April 12 (Reuters) - Nike ( NKE ) is spending more on this Olympics than any previous Games, top executives said on Friday, as the U.S. sportswear brand embarks on a marketing push it hopes will revive flagging sales and help compete with upstart rivals. Sportswear makers are looking to reignite demand on the back of Paris 2024, which...
Centenario Details Phase 2 Exploration Program At Eden Project
Centenario Details Phase 2 Exploration Program At Eden Project
Apr 12, 2024
09:08 AM EDT, 04/12/2024 (MT Newswires) -- Centenario Gold Corp. (CTG.V), at 52 week lows, on Friday outlined the details of the second phase of its exploration program at the Eden property near Prime Mining Corp.'s ( PRMNF ) Los Reyes project in Mexico. Centenario said its geological team is analyzing the recent drill data and reinterpreting the geological information...
Apple Loses Appeal to Dismiss UK Lawsuit Over App Store Fees
Apple Loses Appeal to Dismiss UK Lawsuit Over App Store Fees
Apr 12, 2024
09:06 AM EDT, 04/12/2024 (MT Newswires) -- Apple's ( AAPL ) appeal to throw out a UK mass lawsuit, which accuses the iPhone maker of charging third-party developers excessive and unfair commissions, was rejected, according to the Competition Appeal Tribunal ruling published Friday. In its unanimous decision, the Tribunal said the case has a realistic prospect of establishing that the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved